

1 **Bacteriophage  $\Phi$ M1 of *Pectobacterium* evolves to escape two bifunctional Type III**  
2 **toxin-antitoxin and abortive infection systems through mutations in a single viral**  
3 **gene**

4  
5 **Authors:** Tim R. Blower<sup>1\*</sup>, Ray Chai<sup>1</sup>, Rita Przybilski<sup>2</sup>, Shahzad Chindhy<sup>1</sup>, Xinzhe Fang<sup>1</sup>,  
6 Samuel E. Kidman<sup>1</sup>, Hui Tan<sup>1</sup>, Ben F. Luisi<sup>1</sup>, Peter C. Fineran<sup>2</sup> and George P. C. Salmond<sup>1#</sup>.

7 <sup>1</sup>*Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United*

8 *Kingdom;* <sup>2</sup>*Department of Microbiology and Immunology, University of Otago, P.O. Box 56,*

9 *Dunedin 9054, New Zealand.*

10 *\*Current address: Department of Biosciences, Durham University, South Road, Durham, DH1*

11 *3LE*

12

13 Running head:  **$\Phi$ M1 escapes two Type III TA systems by the same route**

14 **Key words:** Type III toxin-antitoxin,  $\Phi$ M1, *Pectobacterium atrosepticum*, abortive  
15 infection, bacteriophage-bacteria interaction

16

17 **#**Correspondence should be addressed to George P.C. Salmond at Department of Biochemistry,

18 University of Cambridge, Cambridge, CB2 1QW, United Kingdom. Email: gpcs2@cam.ac.uk.

19 Tel. +44(0)1223 333650.

20

21 **ABSTRACT**

22 Some bacteria, when infected by their viral parasites (bacteriophages), undergo a suicidal  
23 response that also terminates productive viral replication (abortive infection; Abi). This response  
24 can be viewed as an altruistic act protecting the uninfected bacterial clonal population. Abortive  
25 infection can occur through the action of Type III protein-RNA toxin-antitoxin (TA) systems,  
26 such as ToxIN<sub>Pa</sub> from the phytopathogen, *Pectobacterium atrosepticum*. Rare spontaneous  
27 mutants evolved in the generalized transducing phage, ΦM1, which escaped ToxIN<sub>Pa</sub>-mediated  
28 abortive infection in *P. atrosepticum*. ΦM1 is a member of the *Podoviridae* and member of the  
29 “KMV-like viruses”, a subset of the T7 supergroup. Genomic sequencing of ΦM1 escape  
30 mutants revealed single-base changes which clustered in a single open reading frame. The  
31 “escape” gene product, M1-23, was highly toxic to the host bacterium when over-expressed, but  
32 mutations in M1-23 that enabled an escape phenotype caused M1-23 to be less toxic. M1-23 is  
33 encoded within the DNA metabolism modular section of the phage genome, and when it was  
34 over-expressed, it co-purified with the host nucleotide excision repair protein, UvrA. While the  
35 M1-23 protein interacted with UvrA in co-immunoprecipitation assays, a UvrA mutant strain  
36 still aborted ΦM1, suggesting that the interaction is not critical for the Type III TA Abi activity.  
37 Additionally, ΦM1 escaped a heterologous Type III TA system (TenpIN<sub>Pt</sub>) from *Photobacterium*  
38 *luminescens* (reconstituted in *P. atrosepticum*) through mutations in the same protein, M1-23.  
39 The mechanistic action of M1-23 is currently unknown but further analysis of this protein could  
40 provide insights into the mode of activation of both systems.

41 **IMPORTANCE**

42 Bacteriophages, the viral predators of bacteria, are the most abundant biological entities and are  
43 important factors in driving bacterial evolution. In order to survive infection by these viruses,  
44 bacteria have evolved numerous anti-phage mechanisms. Many of the studies involved in  
45 understanding these interactions have led to the discovery of biotechnological and gene-editing  
46 tools, most notably restriction enzymes and more recently the CRISPR-Cas systems. Abortive  
47 infection is another such anti-phage mechanism that warrants further investigation. It is unique in  
48 that activation of the system leads to the premature death of the infected cells. As bacteria  
49 infected with the virus are destined to die, undergoing precocious suicide prevents the release of  
50 progeny phage and protects the rest of the bacterial population. This altruistic suicide can be  
51 caused by Type III toxin-antitoxin systems and understanding the activation mechanisms  
52 involved will provide deeper insight into the abortive infection process.

53 **INTRODUCTION**

54 It is estimated that there are more than  $10^{30}$  bacteriophages (phages) on Earth, outnumbering  
55 their bacterial hosts tenfold (1, 2). These large viral numbers generate an estimated  $10^{25}$   
56 infections per second, imposing a large evolutionary selection pressure on bacteria (2). In  
57 response, bacteria have evolved a plethora of defensive mechanisms to counter these  
58 overwhelming phage insults (3). Consequently, phages are continually evolving counter defences  
59 and thus both the host and parasite are locked together in a perpetual molecular arms race (4).  
60 Bacterial anti-phage mechanisms that have been observed include adsorption prevention,  
61 restriction-modification systems, superinfection systems, abortive infection (Abi) systems and  
62 the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas systems (3). Studies  
63 of these phage-host interactions have been translated into significant molecular technologies and  
64 reagents, most notably the use of restriction enzymes in cloning (5) and, more recently the  
65 CRISPR-Cas systems use of which is currently revolutionising eukaryotic molecular biology (6).

66 One of the more curious anti-phage mechanisms is Abi where, post-infection, the host  
67 bacterium is driven towards precocious cell death. This simultaneously terminates viral  
68 replication and prevents a productive phage burst. Thus, the Abi response in infected cells  
69 protects the bacterial population from progeny phage infection in a process akin to an altruistic  
70 suicide (3). The majority of Abi systems have been studied in *Lactococcus lactis* (7), an  
71 important bacterium in the dairy industry (8). Phage contamination in fermentation cultures can  
72 cause substantial economic losses. Consequently, considerable research has been conducted to  
73 identify and define many anti-phage systems useful for control of bacteriophages in lactococcal  
74 fermentations (7). However, there are also well-studied Abi systems in other bacteria such as  
75 *Escherichia coli*, namely the Rex, Lit and PrrC systems (9-11). A commonly recurring theme of

76 Abi systems is that they involve the activation of a toxic protein that is suppressed under normal  
77 growth conditions. However, environmental insults, phages, or other physiological stresses can  
78 activate the toxin. Once activated, the toxin interferes with an essential cellular process and  
79 induces bacteriostasis, ultimately leading to cell death. This is a common feature shared by toxin-  
80 antitoxin systems (12).

81 Toxin-antitoxin (TA) systems were originally discovered on plasmids where they  
82 function as plasmid maintenance systems through post-segregational killing mechanisms (13).  
83 They have been found in the majority of bacteria, both on plasmids (13) and chromosomally  
84 (14), as well as in archaea (15) and phages (16). TA systems are typically bicistronic, comprising  
85 a bacteriostatic or bactericidal toxic protein that is neutralized either directly or indirectly by an  
86 antitoxin counterpart. To date there are six TA system Types which are characterized by the  
87 nature and mode of action of their antitoxins (17). In the case of Type III TA systems, an RNA  
88 antitoxin directly interacts with the toxic protein to form a non-toxic complex (18).

89 At least four Types of TA systems confer phage resistance. These are the *hok/sok* systems  
90 of Type I (19), *mazEF*, *rnlAB* and *IsoAB* of Type II (20, 21), *ToxIN<sub>Pa</sub>*, *TenpIN<sub>Pl</sub>* and *AbiQ* of  
91 Type III (22-24), *AbiE* of Type IV (25) and *sanaTA* (which is currently not characterized but  
92 likely to be a Type II, having a proteinaceous antitoxin) (26). *ToxIN<sub>Pa</sub>* was the first Type III  
93 system to be identified and originated from *Pectobacterium atrosepticum* plasmid pECA1039.  
94 The toxin *ToxN<sub>Pa</sub>* is encoded by *toxN* and the antitoxin *ToxI<sub>Pa</sub>* is encoded by *toxI*, a 36 nucleotide  
95 sequence repeated five and a half times (22). The *ToxIN<sub>Pa</sub>* system provides protection against  
96 multiple phages infecting not only its cognate host, *P. atrosepticum*, but also other enteric  
97 bacteria including *E. coli* DH5 $\alpha$  and *Serratia marcescens* Db11 (22). One such aborted  
98 pectobacterial phage is the *Myoviridae* phage,  $\Phi$ TE.  $\Phi$ TE phages that were no longer sensitive to

99 ToxIN<sub>Pa</sub> had evolved to encode an RNA antitoxic mimic of ToxI<sub>Pa</sub>, which was able to neutralize  
100 ToxN<sub>Pa</sub> (27). However, it did not shed light on how ToxIN<sub>Pa</sub> was activated during phage  
101 infection. In fact, very little is known about the activation of any Type III toxin-antitoxin  
102 systems. The other Type III system that has been studied for *Abi* is *AbiQ* from *Lactococcus*  
103 *lactis*, which shows structural homology with ToxN<sub>Pa</sub> (24). Three lactococcal siphophages that  
104 were aborted by *AbiQ* have been examined in detail. However, all had mutations in genes of  
105 unknown functions; *orf38*, *m1* and *e19* of phages P008, bIL170 and *c2*, respectively (28). The  
106 *AbiQ* system was also reconstructed in a heterologous host, *E. coli* MG1655, and was shown to  
107 confer resistance to a range of coliphages including T4 and T5. However, escape mutants could  
108 only be obtained for a single phage (Phage 2). Escapes of this phage showed mutations in *orf210*,  
109 a predicted DNA polymerase (28). Studies of the *AbiQ* system suggests there may be multiple  
110 potential routes of escape involving several genes from different phages in the activation of a  
111 single *Abi* system.

112 Previously it was shown that the *Pectobacterium* phage,  $\Phi$ M1, was aborted by the ToxIN<sub>Pa</sub>  
113 system and was able to escape by evolving rare mutants (29).  $\Phi$ M1 was isolated in 1995 during a  
114 search for new transducing phages effective as genetic tools in *P. atrosepticum* (30). Here we  
115 characterize  $\Phi$ M1 and its escape mutants in depth. All  $\Phi$ M1 escape phages evolved through  
116 mutations in a gene encoding a small highly toxic protein, M1-23. When the related TenpIN<sub>P1</sub>  
117 system of *Photorhabdus luminescens* was transferred to *P. atrosepticum*, the system was able to  
118 abort  $\Phi$ M1 in the heterologous host. Furthermore, it was possible to select spontaneous viral  
119 mutants that escaped both ToxIN<sub>Pa</sub> and TenpIN<sub>P1</sub> through mutations in M1-23.

120

121

## 122 MATERIALS AND METHODS

### 123 Bacterial strains, bacteriophages and growth conditions

124 Bacterial strains and bacteriophages are listed in Table 1. *E. coli* strains were grown at 37°C and  
125 *Pectobacterium atrosepticum* SCRI1043 (Pba) (31) was grown either at 25°C on agar plates or at  
126 25, 28, or 30°C as required for liquid culture, in Luria broth (LB) at 250 rpm or on LB-agar  
127 (LBA). LBA contained 1.5% w v<sup>-1</sup> or 0.35% w v<sup>-1</sup> agar, to make LBA plates or top-LBA,  
128 respectively. Bacterial growth was measured using a spectrophotometer set to 600 nm. When  
129 required, media were supplemented with ampicillin (Ap) at 100 µg ml<sup>-1</sup>, chloramphenicol (Cm)  
130 at 50 µg ml<sup>-1</sup>, kanamycin (Km) at 50 µg ml<sup>-1</sup>, tetracycline (Tc) at 10 µg ml<sup>-1</sup>, Isopropyl β-D-  
131 thiogalactopyranoside (IPTG) at 0.5 mM or 2, 6-diaminopimelic acid (DAPA) at 300 µM.  
132 Phage spontaneous escape mutants were isolated as described previously (27). Phage lysates  
133 were made as described (32). Phages were stored at 4°C in phage buffer; 10 mM Tris-HCl pH  
134 7.4, 10 mM MgSO<sub>4</sub>, 0.01% w v<sup>-1</sup> gelatin. A few drops of chloroform saturated with sodium  
135 bicarbonate was also added to the phage lysates to maintain sterility. Efficiency of Plating (EOP)  
136 was calculated after overnight incubation of serial dilutions of phage lysates in a top-LBA lawn  
137 of each bacterial host, and recorded as plaque forming units (pfu) on test strain/pfu on control  
138 strain. EOPs were calculated using Pba wild type (wt) or a frame-shifted *toxN* plasmid strain as  
139 the negative control (22).

140

### 141 ΦM1 genomic sequencing

142 Bacteriophage DNA was extracted with phenol/chloroform, using phase-lock gel tubes  
143 (Eppendorf) and following the manufacturer's instructions, as for bacteriophage λ. The extracted  
144 DNA was subjected to pyrosequencing on a Roche 454 Genome Sequencer FLX at the DNA

145 sequencing facility, Department of Biochemistry, University of Cambridge. Contiguous read  
146 segments (contigs) were assembled using Newbler (Roche). The  $\Phi$ M1 wild type sequence was  
147 determined in one lane of the sequencing run. The three escape phage genomes were individually  
148 tagged with independent identifying sequences, then combined and sequenced as a mixture  
149 within a second lane. For each of the four phages, the final assembled sequence consisted of a  
150 single contig of approximately 43,500 base-pairs (bp). The average read length was 250 bp. The  
151 wild type sequence was assembled from 13,628 reads, leading to approximately 78x coverage of  
152 the full sequence. Escape phage  $\Phi$ M1-A, -B and -D sequences were assembled from 4925, 5188  
153 and 5886 reads, respectively, resulting in approximately 29x coverage of each sequence.

154         When viewing the sequence data, beginning at 43,572 bp (in the final  $\Phi$ M1 wt sequence),  
155 there were fifteen tandem repeats of the 2 bp sequence ‘TG’. The number of TG repeats varied  
156 between the raw sequences of each phage, from seventeen in  $\Phi$ M1-A to one in  $\Phi$ M1-B and  
157 seven in  $\Phi$ M1-D. The exact number of TG repeats in each phage genome could not be accurately  
158 confirmed by sequencing a specific amplicon. Therefore, in order to sequence this region, it was  
159 specifically amplified (Primers TRB107/108 and TRB115/116) and cloned into pBR322 (NEB).  
160 From the resulting plasmid DNA, the region was successfully sequenced on both forward and  
161 reverse strands.

162         Potential ORFs were identified using gene prediction tools such as ORFfinder  
163 (<http://www.ncbi.nlm.nih.gov/projects/gorf/>), GeneMark.hmm (33) and Glimmer (34), along  
164 with BLAST (35) homology searches and manual annotation. RBSfinder (36) was used to  
165 predict ribosome-binding sites (Table S1).  $\Phi$ M1 tRNAs were identified using tRNAScan-SE  
166 (37). The BDGP Neural Network Promoter Prediction (38) program did not identify any  
167 consensus promoters. The program, “Stretcher”, from the EMBOSS suite



168 ([http://www.ebi.ac.uk/Tools/psa/emboss\\_stretcher/nucleotide.html](http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/nucleotide.html)), was used for global  
169 nucleotide alignments. The  $\Phi$ M1 genome was viewed and annotated using Artemis (39).

170

### 171 **Plasmid construction**

172 Molecular biology techniques were performed as described previously (40). All primers were  
173 obtained from Sigma-Genosys and Invitrogen and are listed in Table 2. All plasmids constructed  
174 and/or used in this study are listed in Table 3, along with the primers used for their construction.  
175 All recombinant plasmid sequences were verified by DNA sequencing.

176

### 177 **Measuring ToxI<sub>Pa</sub> and ToxN<sub>Pa</sub> Levels during Phage Infection**

178 Two cultures of 180 ml LB containing Ap were inoculated with 2 ml overnight cultures of Pba  
179 (pBR322) or Pba (pMJ4), respectively. Cultures were grown at 25°C and shaken at 180 rpm to  
180 an OD<sub>600</sub> of 1 and each split into 2 × 80 ml; one of which was infected with phage at a  
181 multiplicity of infection (MOI) of 1, while the other served as a negative control without  
182 infection. Cultures were left for 10 min without shaking for phage adsorption, then shaken at  
183 25°C and 180 rpm. Samples for OD<sub>600</sub> measurement, RNA preparation and protein analysis were  
184 taken regularly during infection. Total RNA was isolated using the TRIZOL method and  
185 subsequently DNase treated. Cell pellets for Western blot analysis were resuspended in 1 × PBS  
186 according to OD<sub>600</sub> measurement.

187

### 188 **Western blot analysis of ToxN<sub>Pa</sub> during infection**

189 One ml samples of the cell cultures were taken, pelleted and resuspended in 1 × PBS according to  
190 OD<sub>600</sub>. For samples taken during  $\Phi$ M1 phage infection, the protein was quantified using a

191 Nanodrop (ThermoScientific) and equal amounts of protein (150  $\mu\text{g}$ ) were resolved by 12%  
192 PAGE. Proteins were transferred to a PVDF-membrane and blocked for 1 h in 1 $\times$  PBS  
193 containing 5% milk powder. Immunodetection of FLAG-tagged ToxN was performed overnight  
194 at 4°C in 1 $\times$  PBS using anti-FLAG M2 antibody (Sigma). Goat anti-mouse IgG-HRP (Santa  
195 Cruz) was used as secondary antibody. Bands were visualized on X-Ray film using the  
196 SuperSignal West Pico Chemiluminescent Substrate Kit (Pierce). SdhE-FLAG expressed from  
197 pMAT7 (41), was used as a control in the blot tracking  $\Phi\text{M1}$  infection.

198

### 199 **S1-nuclease Protection Assays**

200 An antisense probe covering the complete ToxI<sub>Pa</sub> sequence was made by amplification of the  
201 ToxI<sub>Pa</sub> locus from plasmid pTA110, using primers PF217 and PF218, and subsequent *in vitro*  
202 transcription and gel extraction of the probe as described (42), generating a uniformly <sup>32</sup>P-UTP  
203 labeled antisense transcript. Ten  $\mu\text{g}$  of DNase-treated total RNA was hybridized to the antisense  
204 probe overnight at 68°C in a total volume of 30  $\mu\text{l}$  containing 22% or 6% formamide for the  
205  $\Phi\text{M1}$  and  $\Phi\text{M1-O}$  total RNA, respectively, 40 mM PIPES/KOH (pH 6.4), 1 mM EDTA and 400  
206 mM NaCl. Reactions were treated with S1-nuclease (Invitrogen) (1 U  $\mu\text{l}^{-1}$ ) for 1.5 h at 37°C in a  
207 total volume of 300  $\mu\text{l}$  1 $\times$  S1-nuclease buffer, to degrade any single-stranded nucleic acids.  
208 Double-stranded hybridization products were precipitated, resuspended and resolved by 10%  
209 PAGE. Bands were visualized by phosphorimaging (BioRad Personal FX phosphorimager).

210

211

212 **Toxicity assays**

213 When required, media were supplemented with Ap, D-glucose (glu) at 0.2% w v<sup>-1</sup> and L-  
214 arabinose (L-ara) at 0.1% w v<sup>-1</sup>. Pba strains containing two plasmids were grown as 10 ml  
215 overnight cultures, then used to inoculate 25 ml LB, Ap, Cm and glu in 250 ml conical flasks,  
216 and grown at 25°C and 250 rpm, from a starting OD<sub>600</sub> of ~0.04, until exponential phase (~1 x  
217 10<sup>8</sup> colony forming units (cfu) ml<sup>-1</sup>). Samples were removed, washed with phosphate buffered  
218 saline (PBS), serially diluted and plated for viable counts at 25°C on LBA, Ap, Cm plates  
219 containing either i) glu, to repress expression or; ii) L-ara, to induce expression. Single plasmid  
220 strains were treated in the same way, except omitting Cm from the growth conditions.

221

222 **β-galactosidase assays**

223 Liquid assays for LacZ activity were performed using the substrate 4'-Methylumbelliferyl-β-D-  
224 glucuronide (MUG) as described before (43). Briefly, samples of culture (150 μl) were taken at  
225 each time point and frozen at -80°C until required. Ten μl aliquots of each sample culture were  
226 frozen at -80°C for 10 min and then thawed at room temperature. Next, 100-μl reaction buffer  
227 (PBS, 400 μg ml<sup>-1</sup> lysozyme, 250 μg ml<sup>-1</sup> MUG) was added and samples were immediately  
228 monitored in a Gemini XPS plate reader with the following parameters: excitation 360 nm,  
229 emission 450 nm, cut-off 435 nm, eight reads per well, and measured every 30 s for 30 min. RFU  
230 min<sup>-1</sup> was calculated from a period of linear increase in fluorescence, normalized to the OD<sub>600</sub> of  
231 the sample.

232

233

234

235 **Pulldown of ToxIN<sub>Pa</sub> and M1-23 from cell lysates**

236 Using  $\Phi$ M1 and  $\Phi$ M1-O genomic DNA (gDNA),  $\Phi$ M1-23 and M1-O-23 were amplified via  
237 PCR using TRB111 and TRB135 as primers. The products were then digested using the relevant  
238 restriction enzymes, ligated into pQE-80L and then used to transform ER2566. For the ToxIN<sub>Pa</sub>  
239 strains, pMJ4 (which contains ToxIN<sub>Pa</sub>-FLAG) was used and a new plasmid was constructed to  
240 make a ToxN<sub>Pa</sub>-chitin binding domain (CBD) fusion. This was produced using pTA46 and  
241 primers TRB37 and TRB38. The plasmid pTRB14 was then used to transform ER2566 which  
242 had previously been transformed with pTRB18-KP14 that contains a ToxI<sub>Pa</sub> sequence.

243 Expression strains were grown in 2xYT media (per litre: 16 g tryptone, 10 g yeast extract,  
244 5 g NaCl) at 37°C until an OD<sub>600</sub> of approximately 1. The cultures were then induced with the  
245 appropriate supplement (0.5 mM IPTG for M1-23-6His and M1-O-23-6His) and then left to  
246 grow overnight at 18°C. No inducers were added to the tagged ToxIN<sub>Pa</sub> containing strains as it is  
247 constitutively expressed on pBR322.

248 Cells were harvested by centrifugation at 8,000 x g and the pellets were re-suspended in  
249 10 ml lysis buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, 500 mM NaCl, 10 mM imidazole, 10% glycerol, pH  
250 8.0) per 500 ml of original culture volume. Cells were then lysed by four passes through a high-  
251 pressure homogeniser (emulsiflex at up to 15,000 psi). Lysed cells were centrifuged at 8,000 x g  
252 and the supernatants kept for further co-immunoprecipitation experiments.

253 In the experiments using M1-23-6His and M1-O-23-6His as bait, 1.5 ml Ni<sup>2+</sup> resin  
254 columns were used with ToxIN<sub>Pa</sub>-FLAG. The columns were equilibrated using 3 column  
255 volumes (CV) of lysis buffer before loading of the His-tagged protein lysates onto the resin.  
256 Loaded resins were washed with 5 column volumes (CV) of wash buffer 1 (20 mM imidazole)  
257 followed by 10 CV of wash buffer 2 (40 mM imidazole). The FLAG-tagged ToxIN<sub>Pa</sub> was then

258 loaded onto the appropriate columns via continuous flow for at least 3 h (often overnight) before  
259 washing with 5 CV wash buffer 1 and 10 CV wash buffer 2.

260 Samples were eluted from the resin using elution buffer (250 mM imidazole) via 3 x 1 ml  
261 fractions and analysed by western blot analysis using antibodies against His- (Novagen) and  
262 FLAG- (Sigma) tags. Briefly, samples were run on 12.5 % Tris-tricine gels and transferred onto  
263 Immobilon-P PVDF membranes (pore size: 0.45  $\mu$ m; Millipore) at 250 mA for 90 min.  
264 Membranes were then blocked with a 5% milk + PBST solution for 1 h before incubation with  
265 anti-His and anti-FLAG antibodies at 1:10,000 for 2 h. After incubation, the membranes were  
266 washed 3x 5 min in PBST and then incubated with the secondary anti-mouse antibody (Sigma) at  
267 1:10,000 for 1 h before washing again 3x 5 min in PBST. The blots were then probed with  
268 Immobilon-Western chemiluminescent HRP-substrate (Millipore) and developed.

269 For experiments where ToxIN<sub>Pa</sub> was used as the bait, the strain expressing ToxIN<sub>Pa</sub>-CBD  
270 was used with a 1 ml chitin resin. The protocol and buffers used were as described by the  
271 manufacturer (NEB). Briefly, the ToxIN<sub>Pa</sub>-CBD lysate was loaded onto the column and washed  
272 with 40 ml of column buffer. The M1-23 or control pQE-80L lysates were then added onto their  
273 respective columns. The columns were washed twice with 10 ml then 27 ml of column buffer  
274 followed by a DTT flush, 5-7 ml for 10 min. Columns were then left to incubate overnight at  
275 room temperature. After incubation, elution was carried out using 15 ml of column buffer.  
276 Western blots were then performed on the samples as previously described.

277

### 278 **Measuring ToxI<sub>Pa</sub> levels after ToxIN<sub>Pa</sub> pulldowns with M1-23**

279 ToxI<sub>Pa</sub> levels were measured in the eluted fractions of the ToxIN<sub>Pa</sub>-CBD, chitin resin column  
280 experiments. Samples from cultures expressing either M1-23 or containing the pQE-80L vector

281 control were separated by electrophoresis at 80 volts, using a 1% w v<sup>-1</sup> agarose gel made with  
282 0.5x TAE. Additionally, samples were also measured by Nanodrop (Labtech, ND-1000).

283

#### 284 **Co-immunoprecipitation of UvrA and M1-23**

285 UvrA-6His was constructed by amplification from the *E. coli* W3110 genome using primers  
286 TRB337 and TRB338. PCR products were then digested with the appropriate restriction  
287 enzymes and the digested product was purified, then ligated into pQE-80L to generate UvrA  
288 with an N-terminal His-tag, pTRB301. This plasmid was then used to transform the *E. coli*  
289 expression strain ER2566. Likewise, UvrA-FLAG was constructed in a similar way but using  
290 primers TRB330 and TRB332 and ligated into pBAD33.

291 Expression and subsequent experiments were performed as described earlier using His-  
292 tagged proteins as bait on Ni<sup>2+</sup> resin. Expression of UvrA-FLAG was induced by addition of  
293 0.02% arabinose.

294

#### 295 **Construction of the *P. atrosepticum* *uvrA* mutant**

296 The *uvrA* mutant of Pba was constructed via allelic exchange. This was performed using the  
297 plasmid pKNG-uvrA, which was derived from pKNG101. The plasmid was constructed by  
298 firstly amplifying 500 bp regions up- and downstream of the *uvrA* gene in *P. atrosepticum*  
299 SCRI1043. These two sequences were then ligated together with a kanamycin cassette inserted  
300 in-between.

301 The suicide vector derivative, pKNG-uvrA, was used to transform *E. coli*  $\beta$ 2163 and  
302 grown overnight in the appropriate selective media. This acted as the donor strain and, along

303 with an overnight of the recipient strain, *P. atrosepticum* SCRI1043, was pelleted and  
304 resuspended in LB. Both cultures were then mixed in the ratios of 2:1, 1:1 and 1:2 up to a final  
305 volume of 100  $\mu$ l. The resulting mixtures were then spotted on to DAPA-containing plates and  
306 incubated at 25°C for 24 h. After mating, the patches were resuspended in 100  $\mu$ l LB, serially  
307 diluted and spread onto LBA plates containing tetracycline. These plates were incubated for 2 d at  
308 25°C and colonies that appeared were picked and grown in LB overnight. The subsequent  
309 overnight cultures were serially-diluted and 50  $\mu$ l samples plated onto LBA plates containing  
310 10% w v<sup>-1</sup> sucrose. Colonies were also patched onto LBA plates containing kanamycin and the  
311 gene deletion was confirmed using colony PCR and DNA sequencing. The strain was confirmed  
312 phenotypically as UvrA-negative by demonstrating a hypersensitivity to UV light (Fig. S1).

313

#### 314 **Genomic sequence accession number**

315 The genome of  $\Phi$ M1 has been submitted to GenBank under the accession number JX290549.

316

317

318

319

320

321

322

323 **RESULTS**

324 **ΦM1 is a 'KMV-like' virus**

325 ΦM1 is a generalized transducing phage of *Pectobacterium atrosepticum* (Pba; previously  
326 *Erwinia carotovora* subsp. *atroseptica*) (30). This Podovirus is aborted by the Type III TA  
327 system, ToxIN from Pba, ToxIN<sub>Pa</sub> (22). ΦM1 generates spontaneous 'escape' mutants that are  
328 resistant to Abi by ToxIN<sub>Pa</sub>, at a rate of  $\sim 10^{-5}$  (29). In order to improve our understanding of  
329 ToxIN<sub>Pa</sub>-phage interactions we sequenced ΦM1 wt and three previously isolated escape phages,  
330 ΦM1-A, -B and -D (29).

331 Using BLAST searches (35), ΦM1 was classified as a member of the "KMV-like"  
332 subgroup of the T7 supergroup of phages (44). T7-like phage linear genomes are typically  
333 flanked by direct terminal repeats (DTRs) (45). However, the DTRs could not be defined by a  
334 'primer walking' strategy along the ΦM1 genome, consistent with results from another "KMV-  
335 like" phage, LIMEzero (46). The presence and approximate size of the DTRs, 293 bp, was  
336 therefore confirmed through restriction digest analysis of the ΦM1 genome (Fig. S2). The final  
337 ΦM1 wild type genome was 43,827 bp long with a GC content of 49.30%. In comparison, the  
338 host Pba genome has a GC content of 50.97% (31). The two genomes therefore closely match  
339 one another in GC content.

340 Global nucleotide alignments were performed to assess the relationship between the  
341 "KMV-like" phages and ΦM1. When compared with ΦM1, phage VP93 (43,931 bp) (47), phage  
342 LKA1 (41,593 bp) (44), phage LKD16 (43,200 bp) (44) and ΦKMV itself (42,519 bp) (45)



343 shared between 48.2% to 49.2% sequence identity. These values match well to those of other  
344 “KMV-like” phages (46).

345  $\Phi$ M1 encodes 52 putative genes, named *phiM1-1* to *phiM1-52*. The gene products were  
346 named M1-1 to M1-52 and they are encoded by 92.6% of the genome. Subsequent BLASTp  
347 searches identified homologues for 32 of the ORFs, from other “KMV-like” phages (Table S1).  
348 In most cases it was therefore possible to assign putative functions and categorize ORFs as  
349 encoding either metabolism, structural or host lysis genes (Fig. 1A).  $\Phi$ M1 also encodes a single  
350 tRNA<sup>Ile</sup>, between *phiM1-38* and *phiM1-39*.

351

### 352 **$\Phi$ M1 escape mutations had specific base substitutions**

353 The genome sequences of the three escape phages, M1-A, -B and -D, were compared with that of  
354 the wt. All three escape phages had single point mutations localized to a 124 bp stretch (Fig. 1B),  
355 across *phiM1-22* and *phiM1-23*, which we refer to as the “escape locus”. To ascertain whether  
356 these point substitutions were individual changes, further escape phages were isolated using  
357 independent lysates to avoid the possibility of sibling mutants. The new escape phage mutants  
358 were isolated following selection on Pba pTA46 (ToxIN<sub>Pa</sub>) (22, 29). The escape locus of each  
359 phage was sequenced following amplification of the region from the purified genomic DNA. We  
360 observed that all 10 escape phages had unique mutations distributed across 246 bp of the escape  
361 locus (Fig. 1B). Nine of these mutations were base substitutions while one was a single base  
362 deletion (Table 4).

363 **Infection with  $\Phi$ M1 affects the ToxI<sub>P<sub>a</sub></sub>:ToxN<sub>P<sub>a</sub></sub> ratio**

364 Though it has been shown that ToxN<sub>P<sub>a</sub></sub> levels do not alter during an  $\Phi$ M1 phage infection (29), it  
365 was not known how the ToxI<sub>P<sub>a</sub></sub> levels were affected. The identification of the escape phages  
366 provided an opportunity to address this question. To investigate alterations to the ToxI<sub>P<sub>a</sub></sub>:ToxN<sub>P<sub>a</sub></sub>  
367 ratio, we monitored the levels of ToxI<sub>P<sub>a</sub></sub> and ToxN<sub>P<sub>a</sub></sub>-FLAG during the infections by  $\Phi$ M1 and  
368 the escape phage,  $\Phi$ M1-O, within Pba carrying a ToxIN<sub>P<sub>a</sub></sub>-FLAG plasmid (pMJ4). Total protein  
369 and RNA samples were taken at different times after infection and subjected to Western Blot and  
370 S1-nuclease assay, respectively. While ToxN<sub>P<sub>a</sub></sub> levels stayed constant throughout infection (Fig.  
371 2A, lower panel), ToxI<sub>P<sub>a</sub></sub> levels dropped dramatically after 30 minutes compared to an uninfected  
372 control (Fig. 2A). Interestingly, ToxI<sub>P<sub>a</sub></sub> levels increased back to original levels at 60 minutes. In  
373 comparison to the infection with  $\Phi$ M1 wt, ToxI<sub>P<sub>a</sub></sub> levels did not change significantly at 30  
374 minutes during infection with the escape phage  $\Phi$ M1-O (Fig. 2B). The ToxI<sub>P<sub>a</sub></sub> level did decrease  
375 with the  $\Phi$ M1-O infection, but only at 40 minutes (Fig. 2B). The ToxI<sub>P<sub>a</sub></sub> levels were not then  
376 restored, as in the case of  $\Phi$ M1 wt (Fig. 2B).  $\Phi$ M1 appears to activate ToxN<sub>P<sub>a</sub></sub>, and thereby  
377 initiate Abi, by causing a decrease in the cellular ToxI<sub>P<sub>a</sub></sub> levels, either through direct or indirect  
378 means. In the case of  $\Phi$ M1-O, this activation is prevented due to the mutation in M1-23. This  
379 would allow the phage to propagate, which may then account for the delayed decrease and lack  
380 of restoration in ToxI<sub>P<sub>a</sub></sub> levels.

381

382

383

384 **Identification and characterization of the  $\Phi$ M1 escape product**

385 The majority of escape mutations occurred within *phiM1-23*. On first analysis, two mutations,  
386 those from  $\Phi$ M1-B and  $\Phi$ M1-X, occurred at the 3' end of *phiM1-22*. Another mutation, from  
387  $\Phi$ M1-C, mapped further upstream, again within *phiM1-22*. This gene, *phiM1-22*, encodes a  
388 homologue of a putative DNA exonuclease from phage LKA1 (Table S1) (44). Unfortunately,  
389 there were no database hits for *phiM1-23* and *phiM1-24*, using either the nucleotide or encoded  
390 protein sequences.

391 Specific regions of this escape locus were amplified from  $\Phi$ M1 phages, then cloned into  
392 pBAD30 (48) to make inducible constructs (Fig. 3A and 3B). The cloning began with constructs  
393 1-6, using DNA from  $\Phi$ M1 wt and  $\Phi$ M1-B (Fig. 3B). Constructs 1 and 2 could not be obtained  
394 with  $\Phi$ M1 wt DNA presumably through toxicity of the resulting wt constructs in *E. coli* DH5 $\alpha$ ,  
395 though could be made using  $\Phi$ M1-B escape phage DNA. Constructs 3, 4, 5 and 6 could be made  
396 using both sources of DNA. Due to the regions covered by these constructs we could determine  
397 that within this locus the genes of interest were *phiM1-22* and *phiM1-23*, and that *phiM1-24* did  
398 not contribute to toxicity. As pBAD30 is tightly repressed by glucose in *E. coli* DH5 $\alpha$ , this also  
399 implied that toxicity from this region of DNA might be occurring via an internal promoter.

400 Upon first analysis, the putative ATG start of *phiM1-23* was at 15,304 bp. Taking into  
401 account the STOP codons of each frame (green vertical lines, Fig. 1B), the putative ATG start  
402 codon of *phiM1-23* could theoretically have been upstream of this initial annotation. There were  
403 three possible ATG sites upstream of the putative start codon for *phiM1-23*. The mutation of  
404  $\Phi$ M1-C specifically altered the middle of these start codons from M to T (Table 4). This start  
405 codon also had a ribosome binding site closer to consensus than those of the other potential start

406 codons, making it the most obvious candidate. If this were the case, the escape mutations would  
407 span *phiM1-23* specifically. Constructs 7-9 were designed and made, in order to test whether  
408 *phiM1-23* alone could generate a toxic phenotype.

409 We performed experiments to assess the toxicity of the escape locus constructs and to  
410 determine whether toxicity was related to the presence of ToxIN<sub>P<sub>a</sub></sub>. Pba was transformed with  
411 inducible derivatives of the escape locus in combination with either pBluescript-based  
412 (Fermentas) ToxIN<sub>P<sub>a</sub></sub> or negative control ToxIN<sub>P<sub>a</sub></sub>-frameshift (FS) vectors (pTRB125 and  
413 pTRB126, respectively). Serial dilutions of these dual-vector strains of Pba were then incubated  
414 with and without induction, overnight, to determine the viable count (Fig. 3C). This clearly  
415 showed that the product of construct 7, covering *phiM1-23* specifically, was toxic. There was no  
416 toxicity in the case of ΦM1-B, the mutation in which causes a premature STOP codon in *phiM1-*  
417 *23*. Toxicity was also independent of the presence of ToxIN<sub>P<sub>a</sub></sub>. These results strongly suggested  
418 that *phiM1-23* produces a small, toxic protein, responsible either directly or indirectly, for  
419 activation of Abi against ΦM1.

420 New versions of construct 7 (Fig. 3D) were then generated, adding a C-terminal FLAG  
421 tag to the M1-23 product, using both ΦM1 wt and escape sequences. Various constructs were  
422 then tested for toxicity in the cognate host, Pba (Fig. 3D). All the escape constructs tested  
423 showed reduced toxicity (Fig. 3D). It was therefore possible to attempt over-expression and  
424 purification of M1-23, using an *E. coli* expression strain, ER2566. After expression trials using  
425 constructs made from ΦM1 wt, -O, -W and -Y phage DNA, the M1-O-23FLAG product was  
426 chosen for further study. Sufficient M1-O-23FLAG protein was purified to allow mass  
427 spectrometry to confirm both the identity of the protein, and specifically the presence of the  
428 expected Q to P mutation. Furthermore, the protein sample was subjected to N-terminal

429 sequencing, generating a sequence of TKM. This implied that *phiM1-23* started at the ATG  
430 specifically mutated by  $\Phi$ M1-C, as described earlier, and that the initial methionine is cleaved  
431 post-translationally. The annotation of the  $\Phi$ M1 wt genome was then altered to accommodate  
432 *phiM1-23* beginning at this confirmed start codon. In summary, this result shows that all the  
433 escape mutations map to a single gene, *phiM1-23*, which generates a 9.8 kDa protein. These  
434 mutations reduce toxicity of the protein product, and allow viral escape from ToxIN<sub>pa</sub>-induced  
435 *Abi*.

436 It had not been possible to clone constructs 1 and 2 (Fig. 3B) using the  $\Phi$ M1 wt  
437 sequence, despite the pBAD30 vector system being repressed in the presence of glucose. This  
438 suggested that a promoter internal to those cloned regions might be inducing transcription of  
439 *phiM1-23*. A range of pRW50-based (49), *lacZ* transcriptional fusion constructs was generated to  
440 investigate the possible presence of a promoter (Fig. S3A). In this case, it was possible to clone  
441 the equivalent of construct 2 using  $\Phi$ M1 wt DNA (Fig. 3B), perhaps due to pRW50 having a low  
442 copy number, so the level of toxicity was sufficiently low. Plasmid pTA104 (22), containing the  
443 promoter for ToxIN<sub>pa</sub>, was used as a positive control. All the test constructs except pTRB162,  
444 which was an extremely truncated clone, generated LacZ activity (Fig. S3B). This confirmed the  
445 presence of a weak *phiM1-23* promoter within *phiM1-22*.

446

#### 447 **Extensive analysis of $\Phi$ M1 escape mutants map all mutations to *phiM1-23***

448 The initial 10 escape mutants of  $\Phi$ M1 all had unique mutations in M1-23, so it was likely that  
449 there were other possible mutations not yet observed. Identifying these other mutations could  
450 reveal important residues involved in the functionality of M1-23. Consequently, a larger library  
451 of escape mutants was isolated and characterized in the same way as the initial escapes. A total

452 of 51 new, independent escape phages were isolated and their *phiM1-23* sequences were  
453 characterized. All escapes were shown to have a mutation in this region and several new unique  
454 escapes were isolated (Table S2). With the addition of these new escapes the number of different  
455 mutations increased to 20. Interestingly, mutations in all three of the bases of the putative start  
456 codon were isolated, consistent with this being the correctly annotated start site. Other interesting  
457 mutations were those causing N-terminally located truncations of M1-23. In particular,  $\Phi$ M1-  
458 E11 produced only a hypothetical dipeptide or indeed just a single amino acid if the initial  
459 starting methionine were removed. Although most mutations in M1-23 were missense alleles  
460 generating single amino acid residue changes, the ability to isolate derivatives with major  
461 truncations showed that the M1-23 protein must be non-essential for a productive  $\Phi$ M1 lytic  
462 cycle. Other notable mutations were  $\Phi$ M1-E48 and 49 (both generating the same outcome),  
463 which modify the stop codon and lead to a 10 amino acid C-terminal extension. It is puzzling  
464 why the 10-mer extension might impact function, because the addition of the octameric FLAG  
465 tag to the C-terminus of M1-23 did not disrupt protein toxicity. Perhaps the extension might  
466 harbour a sequence that could act as an auto-inhibitor or disrupt protein structure.

467

468 **M1-23 interacts with UvrA but abortive infection can still take place in UvrA-**  
469 **deficient *P. atrosepticum***

470 To assess whether there is a direct interaction of M1-23 with the ToxIN<sub>Pa</sub> complex, His-tagged  
471 forms of both M1-23 and M1-O-23 were cloned, allowing over-expression and purification of  
472 these proteins. Co-immunoprecipitation reactions were carried out but the results showed no  
473 evidence for interactions between M1-23 and the ToxIN<sub>Pa</sub> complex, and that M1-23 had no  
474 impact on the ToxI RNA (data not shown).

475 During the process of purifying M1-23-6His it was noted that an additional high  
476 molecular weight band appeared in the eluted sample that was not present in control samples,  
477 which then co-purified with M1-23 following ion exchange FPLC (data not shown). Mass  
478 spectrometric analysis identified the host nucleotide excision repair protein, UvrA. Reciprocal  
479 co-immunoprecipitation assays were performed using purified protein samples to confirm this  
480 interaction (Fig. 4). M1-23 protein retained UvrA while M1-O-23 did not, and similarly, only  
481 M1-23 was retained by immobilized UvrA (Fig. 4). This strongly suggests that M1-23 is a viral  
482 product that is able to bind host UvrA.

483 To assess potential effects of UvrA in abortive infection, a *uvrA* mutant was constructed  
484 in *P. atrosepticum*, confirmed by sequencing and then by hypersensitivity to UV light (Fig. S1).  
485 This strain was tested for its ability to abort  $\Phi$ M1 via the ToxIN<sub>Pa</sub> system. Surprisingly,  $\Phi$ M1  
486 was still aborted in the *uvrA* mutant and to the same extent as in the wild type Pba strain (EOP of  
487  $\Phi$ M1 on *uvrA* mutant with ToxIN<sub>Pa</sub> is  $1.1 \times 10^{-5}$ ). Escapes of  $\Phi$ M1 were isolated from the *uvrA*  
488 mutant and their DNA was sequenced. Interestingly, all escapes isolated on the *uvrA* mutant,  
489  $\Phi$ M1-U1, U2 and  $\Phi$ M1-U4 to U10 (which were independently isolated), carried mutations in the  
490 M1-23 sequence (Table S2). The results suggest that although M1-23 clearly has a specific  
491 interaction with UvrA, it appears that the escape route is either subtle or occurs indirectly.

492

### 493 **The $\Phi$ M1 escape mechanism works in another Type III TA and Abi system**

494 Two further families of Type III TA systems were recently identified, CptIN and TenpIN (23).  
495 TenpIN<sub>Pt</sub>, from the chromosome of *Phototribadus luminescens* TT01, was able to act as an Abi  
496 system against coliphages when cloned on a multicopy plasmid and tested in an *E. coli*

497 background (23). By transforming *P. atrosepticum* SCRI1043 with the TenpIN<sub>P1</sub> expression  
498 plasmid, pFR2 (23), we were able to test three *Pectobacterium* phages against the Abi activity of  
499 TenpIN<sub>P1</sub> (Table 5). While  $\Phi$ S61 (29) and  $\Phi$ TE (27) were dramatically affected by ToxIN<sub>Pa</sub>,  
500 neither were inhibited by TenpIN<sub>P1</sub> (Table 5). This indicates a degree of selectivity between the  
501 two Abi systems.  $\Phi$ M1, however, was aborted by both systems, though to different degrees,  
502 which also underlines the selectivity under which ToxIN<sub>Pa</sub> and TenpIN<sub>P1</sub> appear to operate. As  
503 with ToxIN<sub>Pa</sub>, it was possible to select for phages of  $\Phi$ M1 that escaped Abi by TenpIN<sub>P1</sub>. One of  
504 these escape phages,  $\Phi$ M1-PL2, was isolated and sequenced. This escape phage had a single  
505 base substitution, T15410C, the same mutation as  $\Phi$ M1-D. To test this in reverse, escape phage  
506  $\Phi$ M1-O, selected with ToxIN<sub>Pa</sub>, was tested against TenpIN<sub>P1</sub> (Table 5).  $\Phi$ M1-O was also  
507 resistant to TenpIN<sub>P1</sub>. These results imply that, in the case of  $\Phi$ M1, both systems operate in a  
508 similar fashion with a single protein, M1-23, being a key mediator.

509

510

511

512

513

514

515

516

517



518 **DISCUSSION**

519 The phage  $\Phi$ M1 was shown previously to be sensitive to the ToxIN<sub>Pa</sub> system and  
520 capable of producing spontaneous escape mutants (29). Here we found that the  $\Phi$ M1 phage is  
521 also sensitive to TenpIN<sub>Pt</sub> when reconstructed in *P. atrosepticum* and is correspondingly able to  
522 evolve escape mutants. This is the first time we have been able to identify a phage able to escape  
523 the TenpIN<sub>Pt</sub> system and so further study may provide information about its activation.  
524 Interestingly, the  $\Phi$ M1 phage is insensitive to two other Type III systems tested, ToxIN<sub>Bt</sub> from  
525 *Bacillus thuringiensis* and the CptIN<sub>Er</sub> system from *Eubacterium rectale* (data not shown) and no  
526 Abi activity has so far been observed in these two systems (23, 50). In contrast, the *P.*  
527 *atrosepticum* phage  $\Phi$ TE is aborted by ToxIN<sub>Pa</sub> and able to escape the system by RNA-based  
528 molecular mimicry of the antitoxin (27) but is not aborted by the TenpIN<sub>Pt</sub> system (Table 5).

529 Characterization of the  $\Phi$ M1 phage in this study has shown that all escapes selected on  
530 ToxIN<sub>Pa</sub> or TenpIN<sub>Pt</sub> have mutations in a gene encoding M1-23. Alteration of single amino acids,  
531 extreme truncations due to very 5' stop codons, or even stop codon mutations leading to short C-  
532 terminal extensions of M1-23 cause insensitivity to both ToxIN<sub>Pa</sub> and TenpIN<sub>Pt</sub>. Escapes selected  
533 on one system are also insensitive to the other system, suggesting that there is a common  
534 pathway for the  $\Phi$ M1 phage in the activation of these two systems. The role of M1-23 is  
535 unknown, but it was shown to be non-essential and as it is located between a predicted  
536 exonuclease *phiM1-22* and a predicted endonuclease gene *phiM1-25*, it could have a role in the  
537 regulation of nucleases or indeed may be able to act as a nuclease itself. In a previous study it  
538 was shown that ToxN<sub>Pa</sub> levels do not change during infection of the  $\Phi$ M1 phage (29). In this  
539 study we found that the ToxI<sub>Pa</sub> levels decrease 30 minutes post-infection. In contrast, during the  
540 infection by the  $\Phi$ M1 escape phage,  $\Phi$ M1-O, ToxI<sub>Pa</sub> levels only slightly decreased after 40

541 minutes and were not restored. It appears that wild type  $\Phi$ M1 activates ToxN<sub>Pa</sub> by decreasing the  
542 levels of ToxI<sub>Pa</sub> and therefore initiating Abi. For  $\Phi$ M1-O, the mutation in M1-23 prevents this  
543 early activation and thereby provides a window of opportunity for the phage to replicate.

544 To investigate the mechanism of M1-23 action, a large number of  $\Phi$ M1 escape phages  
545 were isolated and their *phiM1-23* regions were sequenced. The results showed a number of  
546 escape mutations near the 5' end of the gene, resulting in extremely truncated versions of the  
547 protein. This confirms that M1-23 is a non-essential viral protein. However, the majority of  
548 mutations found were towards the 3' region of the gene and were mostly missense mutations  
549 resulting in single amino acid changes, implying that the C-terminal domain of the protein is  
550 important for Abi functionality. To further characterize M1-23, it was overexpressed and purified  
551 but, due to high toxicity, only a small amount of protein could be produced. Using the limited  
552 amount of protein available, interaction studies were performed to see if M1-23 interacted with  
553 ToxIN<sub>Pa</sub>. During purification of M1-23, a high molecular weight protein always co-purified.  
554 Mass spectrometry of this protein confirmed that it was the DNA repair protein UvrA. It was  
555 shown through co-immunoprecipitation experiments that while M1-23 could interact with UvrA,  
556 the escape version of the protein M1-O-23 could not.

557 UvrA forms part of the SOS response in bacteria - a DNA damage response pathway (51)  
558 that has previously been shown to be involved in TA activation. The Type I TA system TisB-  
559 IstR is under direct SOS response control, as *tisAB* which encodes the TisB toxin contains a  
560 LexA operator region that is inhibited by LexA (52). As well as the SOS response, the stringent  
561 response has also been shown to play a role in the activation of TA systems. Both Type I and  
562 Type II TA systems have been shown to be regulated by (p)ppGpp, the central regulator of the

563 stringent response (53, 54). However,  $\Phi$ M1 and  $\Phi$ TE were tested in a (p)ppGpp negative double  
564 mutant (*relA*, *spoT*) and were still aborted in that background (data not shown).

565 During the course of this study, two new pectobacterial phage genomes were sequenced.  
566 These were *P. atrosepticum* phage Peat1 (55), (GenBank accession KR604693) and *P.*  
567 *carotovorum* phage PPWS1 (56), (DDBJ accession number LC063634). Both of these were  
568 podoviruses that shared high sequence identity to  $\Phi$ M1. Peat1 (45,6533 bp) shared 77.7%  
569 sequence identity and PPWS1 (44,539 bp) shared 59.7% sequence identity. Furthermore,  
570 analysis of both genomes revealed that both phages encoded M1-23 homologs with the Peat1  
571 homolog only differing by a single amino acid. Therefore, it is highly likely that both phages  
572 would be aborted by both the ToxIN<sub>Pa</sub> and TenpIN<sub>Pi</sub> systems and evolve escapes in the same  
573 way. If this was the case, it would show a common route through which phages of different  
574 bacteria are able to escape the same system.

575 Both ToxIN<sub>Pa</sub> and TenpIN<sub>Pi</sub> are very powerful anti-phage abortive infection systems that  
576 belong to two different families of Type III TA systems and are effective against a wide variety  
577 of phages. While many phages show differing sensitivity to the two systems, this study has  
578 shown that in  $\Phi$ M1 there is a common pathway through which these two families of Type III TA  
579 systems can be activated. This pathway involves a small toxic protein, M1-23, of unknown  
580 metabolic function that does not directly interact with the ToxIN<sub>Pa</sub> complex, but interacts directly  
581 with UvrA.  $\Phi$ M1 infection causes a diminution in ToxI<sub>Pa</sub> levels presumably leading to the  
582 destabilization of the ToxIN<sub>Pa</sub> complex and consequent liberation of ToxN<sub>Pa</sub> to induce cell death  
583 and concomitant abortive infection of the viral parasite.

584

585 **ACKNOWLEDGEMENTS** This research was funded by support from the Biotechnology and  
586 Biological Sciences Research Council, UK to GPCS and by a Marsden Fund, Royal Society of  
587 New Zealand (RSNZ) award to PCF and GPCS, plus a Rutherford Discovery Fellowship  
588 (RSNZ) to PCF. BFL was supported by the Wellcome Trust, UK.

589 The authors would also like to acknowledge Simon Poulter for the construction of pKNG101-  
590 TC<sup>R</sup> (Table 3).

591

## 592 REFERENCES

- 593 1. **Wommack KE, Colwell RR.** 2000. Virioplankton: viruses in aquatic ecosystems. *Microbiol Mol*  
594 *Biol Rev* **64**:69-114.
- 595 2. **Chibani-Chennoufi S, Bruttin A, Dillmann ML, Brüssow H.** 2004. Phage-host interaction: an  
596 ecological perspective. *J Bacteriol* **186**:3677-3686.
- 597 3. **Dy RL, Richter C, Salmond GP, Fineran PC.** 2014. Remarkable Mechanisms in Microbes to Resist  
598 Phage Infections. *Annu Rev Virol* **1**:307-331.
- 599 4. **Stern A, Sorek R.** 2011. The phage-host arms race: shaping the evolution of microbes. *Bioessays*  
600 **33**:43-51.
- 601 5. **Loenen WA, Dryden DT, Raleigh EA, Wilson GG, Murray NE.** 2014. Highlights of the DNA  
602 cutters: a short history of the restriction enzymes. *Nucleic Acids Res* **42**:3-19.
- 603 6. **Doudna JA, Charpentier E.** 2014. Genome editing. The new frontier of genome engineering with  
604 CRISPR-Cas9. *Science* **346**:1258096.
- 605 7. **Chopin MC, Chopin A, Bidnenko E.** 2005. Phage abortive infection in lactococci: variations on a  
606 theme. *Curr Opin Microbiol* **8**:473-479.
- 607 8. **Cavanagh D, Fitzgerald GF, McAuliffe O.** 2015. From field to fermentation: the origins of  
608 *Lactococcus lactis* and its domestication to the dairy environment. *Food Microbiol* **47**:45-61.
- 609 9. **Parma DH, Snyder M, Sobolevski S, Nawroz M, Brody E, Gold L.** 1992. The Rex system of  
610 bacteriophage lambda: tolerance and altruistic cell death. *Genes Dev* **6**:497-510.
- 611 10. **Georgiou T, Yu YN, Ekunwe S, Buttner MJ, Zuurmond A, Kraal B, Kleanthous C, Snyder L.** 1998.  
612 Specific peptide-activated proteolytic cleavage of *Escherichia coli* elongation factor Tu. *Proc Natl*  
613 *Acad Sci U S A* **95**:2891-2895.
- 614 11. **Penner M, Morad I, Snyder L, Kaufmann G.** 1995. Phage T4-coded Stp: double-edged effector of  
615 coupled DNA and tRNA-restriction systems. *J Mol Biol* **249**:857-868.

- 616 12. **Yamaguchi Y, Park JH, Inouye M.** 2011. Toxin-antitoxin systems in bacteria and archaea. *Annu*  
617 *Rev Genet* **45**:61-79.
- 618 13. **Gerdes K, Rasmussen PB, Molin S.** 1986. Unique type of plasmid maintenance function:  
619 postsegregational killing of plasmid-free cells. *Proc Natl Acad Sci U S A* **83**:3116-3120.
- 620 14. **Ramage HR, Connolly LE, Cox JS.** 2009. Comprehensive functional analysis of *Mycobacterium*  
621 *tuberculosis* toxin-antitoxin systems: implications for pathogenesis, stress responses, and  
622 evolution. *PLoS Genet* **5**:e1000767.
- 623 15. **Christensen SK, Gerdes K.** 2003. RelE toxins from bacteria and Archaea cleave mRNAs on  
624 translating ribosomes, which are rescued by tmRNA. *Mol Microbiol* **48**:1389-1400.
- 625 16. **Lehnherr H, Maguin E, Jafri S, Yarmolinsky MB.** 1993. Plasmid addiction genes of bacteriophage  
626 P1: doc, which causes cell death on curing of prophage, and phd, which prevents host death  
627 when prophage is retained. *J Mol Biol* **233**:414-428.
- 628 17. **Page R, Peti W.** 2016. Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nat*  
629 *Chem Biol* **12**:208-214.
- 630 18. **Brantl S, Jahn N.** 2015. sRNAs in bacterial type I and type III toxin-antitoxin systems. *FEMS*  
631 *Microbiol Rev* **39**:413-427.
- 632 19. **Pecota DC, Wood TK.** 1996. Exclusion of T4 phage by the hok/sok killer locus from plasmid R1. *J*  
633 *Bacteriol* **178**:2044-2050.
- 634 20. **Hazan R, Engelberg-Kulka H.** 2004. *Escherichia coli* mazEF-mediated cell death as a defense  
635 mechanism that inhibits the spread of phage P1. *Mol Genet Genomics* **272**:227-234.
- 636 21. **Otsuka Y, Yonesaki T.** 2012. Dmd of bacteriophage T4 functions as an antitoxin against  
637 *Escherichia coli* LsoA and RnIA toxins. *Mol Microbiol* **83**:669-681.

- 638 22. **Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GP.** 2009. The phage  
639 abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. *Proc Natl Acad*  
640 *Sci U S A* **106**:894-899.
- 641 23. **Blower TR, Short FL, Rao F, Mizuguchi K, Pei XY, Fineran PC, Luisi BF, Salmond GP.** 2012.  
642 Identification and classification of bacterial Type III toxin-antitoxin systems encoded in  
643 chromosomal and plasmid genomes. *Nucleic Acids Res* **40**:6158-6173.
- 644 24. **Samson JE, Spinelli S, Cambillau C, Moineau S.** 2013. Structure and activity of AbiQ, a  
645 lactococcal endoribonuclease belonging to the type III toxin-antitoxin system. *Mol Microbiol*  
646 **87**:756-768.
- 647 25. **Dy RL, Przybilski R, Semeijn K, Salmond GP, Fineran PC.** 2014. A widespread bacteriophage  
648 abortive infection system functions through a Type IV toxin-antitoxin mechanism. *Nucleic Acids*  
649 *Res* **42**:4590-4605.
- 650 26. **Sberro H, Leavitt A, Kiro R, Koh E, Peleg Y, Qimron U, Sorek R.** 2013. Discovery of functional  
651 toxin/antitoxin systems in bacteria by shotgun cloning. *Mol Cell* **50**:136-148.
- 652 27. **Blower TR, Evans TJ, Przybilski R, Fineran PC, Salmond GP.** 2012. Viral evasion of a bacterial  
653 suicide system by RNA-based molecular mimicry enables infectious altruism. *PLoS Genet*  
654 **8**:e1003023.
- 655 28. **Samson JE, Bélanger M, Moineau S.** 2013. Effect of the abortive infection mechanism and type  
656 III toxin/antitoxin system AbiQ on the lytic cycle of *Lactococcus lactis* phages. *J Bacteriol*  
657 **195**:3947-3956.
- 658 29. **Blower TR, Fineran PC, Johnson MJ, Toth IK, Humphreys DP, Salmond GP.** 2009. Mutagenesis  
659 and functional characterization of the RNA and protein components of the toxIN abortive  
660 infection and toxin-antitoxin locus of *Erwinia*. *J Bacteriol* **191**:6029-6039.

- 661 30. **Toth IK, Mulholland V, Cooper V, Bentley S, Shih Y, -L, Perombelon MCM, Salmond GPC.** 1997.  
662 Generalized transduction in the potato blackleg pathogen *Erwinia carotovora* subsp. *atroseptica*  
663 by bacteriophage phi M1. *Microbiology* **143**:2433-2438.
- 664 31. **Bell KS, Sebaihia M, Pritchard L, Holden MT, Hyman LJ, Holeva MC, Thomson NR, Bentley SD,**  
665 **Churcher LJ, Mungall K, Atkin R, Bason N, Brooks K, Chillingworth T, Clark K, Doggett J, Fraser**  
666 **A, Hance Z, Hauser H, Jagels K, Moule S, Norbertczak H, Ormond D, Price C, Quail MA, Sanders**  
667 **M, Walker D, Whitehead S, Salmond GP, Birch PR, Parkhill J, Toth IK.** 2004. Genome sequence  
668 of the enterobacterial phytopathogen *Erwinia carotovora* subsp. *atroseptica* and  
669 characterization of virulence factors. *Proc Natl Acad Sci U S A* **101**:11105-11110.
- 670 32. **Petty NK, Foulds IJ, Pradel E, Ewbank JJ, Salmond GP.** 2006. A generalized transducing phage  
671 (phiIF3) for the genomically sequenced *Serratia marcescens* strain Db11: a tool for functional  
672 genomics of an opportunistic human pathogen. *Microbiology* **152**:1701-1708.
- 673 33. **Lukashin AV, Borodovsky M.** 1998. GeneMark.hmm: new solutions for gene finding. *Nucleic*  
674 *Acids Res* **26**:1107-1115.
- 675 34. **Delcher AL, Harmon D, Kasif S, White O, Salzberg SL.** 1999. Improved microbial gene  
676 identification with GLIMMER. *Nucleic Acids Res* **27**:4636-4641.
- 677 35. **Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ.** 1990. Basic local alignment search tool. *J*  
678 *Mol Biol* **215**:403-410.
- 679 36. **Suzek BE, Ermolaeva MD, Schreiber M, Salzberg SL.** 2001. A probabilistic method for identifying  
680 start codons in bacterial genomes. *Bioinformatics* **17**:1123-1130.
- 681 37. **Lowe TM, Eddy SR.** 1997. tRNAscan-SE: a program for improved detection of transfer RNA genes  
682 in genomic sequence. *Nucleic Acids Res* **25**:955-964.
- 683 38. **Reese MG.** 2001. Application of a time-delay neural network to promoter annotation in the  
684 *Drosophila melanogaster* genome. *Comput Chem* **26**:51-56.



- 685 39. **Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B.** 2000. Artemis:  
686 sequence visualization and annotation. *Bioinformatics* **16**:944-945.
- 687 40. **Fineran PC, Everson L, Slater H, Salmond GP.** 2005. A GntR family transcriptional regulator  
688 (PigT) controls gluconate-mediated repression and defines a new, independent pathway for  
689 regulation of the tripyrrole antibiotic, prodigiosin, in *Serratia*. *Microbiology* **151**:3833-3845.
- 690 41. **McNeil MB, Clulow JS, Wilf NM, Salmond GP, Fineran PC.** 2012. SdhE is a conserved protein  
691 required for flavinylation of succinate dehydrogenase in bacteria. *J Biol Chem* **287**:18418-18428.
- 692 42. **Przybilski R, Richter C, Gristwood T, Clulow JS, Vercoe RB, Fineran PC.** 2011. Csy4 is responsible  
693 for CRISPR RNA processing in *Pectobacterium atrosepticum*. *RNA Biol* **8**:517-528.
- 694 43. **Ramsay JP, Williamson NR, Spring DR, Salmond GP.** 2011. A quorum-sensing molecule acts as a  
695 morphogen controlling gas vesicle organelle biogenesis and adaptive flotation in an  
696 enterobacterium. *Proc Natl Acad Sci U S A* **108**:14932-14937.
- 697 44. **Ceysens PJ, Lavigne R, Mattheus W, Chibeu A, Hertveldt K, Mast J, Robben J, Volckaert G.**  
698 2006. Genomic analysis of *Pseudomonas aeruginosa* phages LKD16 and LKA1: establishment of  
699 the phiKMV subgroup within the T7 supergroup. *J Bacteriol* **188**:6924-6931.
- 700 45. **Lavigne R, Burkal'tseva MV, Robben J, Sykilinda NN, Kurochkina LP, Grymonprez B, Jonckx B,**  
701 **Krylov VN, Mesyanzhinov VV, Volckaert G.** 2003. The genome of bacteriophage phiKMV, a T7-  
702 like virus infecting *Pseudomonas aeruginosa*. *Virology* **312**:49-59.
- 703 46. **Adriaenssens EM, Van Vaerenbergh J, Vandenheuvel D, Dunon V, Ceysens PJ, De Proft M,**  
704 **Kropinski AM, Noben JP, Maes M, Lavigne R.** 2012. T4-related bacteriophage LIMEstone  
705 isolates for the control of soft rot on potato caused by '*Dickeya solani*'. *PLoS One* **7**:e33227.
- 706 47. **Bastías R, Higuera G, Sierralta W, Espejo RT.** 2010. A new group of cosmopolitan  
707 bacteriophages induce a carrier state in the pandemic strain of *Vibrio parahaemolyticus*. *Environ*  
708 *Microbiol* **12**:990-1000.

- 709 48. **Guzman LM, Belin D, Carson MJ, Beckwith J.** 1995. Tight regulation, modulation, and high-level  
710 expression by vectors containing the arabinose PBAD promoter. *J Bacteriol* **177**:4121-4130.
- 711 49. **Lodge J, Fear J, Busby S, Gunasekaran P, Kamini NR.** 1992. Broad host range plasmids carrying  
712 the *Escherichia coli* lactose and galactose operons. *FEMS Microbiol Lett* **74**:271-276.
- 713 50. **Short FL, Pei XY, Blower TR, Ong SL, Fineran PC, Luisi BF, Salmond GP.** 2013. Selectivity and  
714 self-assembly in the control of a bacterial toxin by an antitoxic noncoding RNA pseudoknot. *Proc*  
715 *Natl Acad Sci U S A* **110**:E241-249.
- 716 51. **Little JW, Mount DW.** 1982. The SOS regulatory system of *Escherichia coli*. *Cell* **29**:11-22.
- 717 52. **Wagner EG, Unoson C.** 2012. The toxin-antitoxin system *tisB-istR1*: Expression, regulation, and  
718 biological role in persister phenotypes. *RNA Biol* **9**:1513-1519.
- 719 53. **Maisonneuve E, Castro-Camargo M, Gerdes K.** 2013. (p)ppGpp controls bacterial persistence by  
720 stochastic induction of toxin-antitoxin activity. *Cell* **154**:1140-1150.
- 721 54. **Verstraeten N, Knapen WJ, Kint CI, Liebens V, Van den Bergh B, Dewachter L, Michiels JE, Fu Q,**  
722 **David CC, Fierro AC, Marchal K, Beirlant J, Versées W, Hofkens J, Jansen M, Fauvart M,**  
723 **Michiels J.** 2015. Obg and Membrane Depolarization Are Part of a Microbial Bet-Hedging  
724 Strategy that Leads to Antibiotic Tolerance. *Mol Cell* **59**:9-21.
- 725 55. **Kalischuk M, Hachey J, Kawchuk L.** 2015. Complete Genome Sequence of Phytopathogenic  
726 *Pectobacterium atrosepticum* Bacteriophage Peat1. *Genome Announc* **3**.
- 727 56. **Hirata H, Kashihara M, Horiike T, Suzuki T, Dohra H, Netsu O, Tsuyumu S.** 2016. Genome  
728 Sequence of *Pectobacterium carotovorum* Phage PPWS1, Isolated from Japanese Horseradish  
729 [*Eutrema japonicum* (Miq.) Koidz] Showing Soft-Rot Symptoms. *Genome Announc* **4**.
- 730 57. **Demarre G, Guérout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marlière P, Mazel D.**  
731 2005. A new family of mobilizable suicide plasmids based on broad host range R388 plasmid

- 732 (IncW) and RP4 plasmid (IncPalpha) conjugative machineries and their cognate *Escherichia coli*  
733 host strains. Res Microbiol **156**:245-255.
- 734 58. **Bachmann BJ.** 1972. Pedigrees of some mutant strains of *Escherichia coli* K-12. Bacteriol Rev  
735 **36**:525-557.
- 736 59. **Chang AC, Cohen SN.** 1978. Construction and characterization of amplifiable multicopy DNA  
737 cloning vehicles derived from the P15A cryptic miniplasmid. J Bacteriol **134**:1141-1156.
- 738 60. **Poulter S.** 2011. The LuxR-family quorum sensing transcriptional regulator CarR in *Erwinia* and  
739 *Serratia*. PhD. University of Cambridge.
- 740
- 741

742 **Figure legends**

743

744 FIG 1 Genomic map of  $\Phi$ M1 wild type and its escape locus. (A) All the fifty-two annotated  
745 ORFs are coded on the forward reading strand, in a linear progression from metabolic genes, to  
746 structural genes and finally host cell lysis genes. Each forward reading frame is labelled; F1, F2  
747 or F3. ORFs are shown to scale as shaded boxes numbered with the gene number, coloured  
748 according to predicted role. The single tRNA<sup>Ile</sup> gene is positioned on the scale, shown in purple.  
749 Where it has been possible to identify a protein by homology searches, that ORF is labelled. The  
750 scale is in base-pairs. The figure was drawn to scale using Adobe Illustrator. (B) Schematic of  
751 the escape locus of  $\Phi$ M1. All escape phage mutations are within *phiM1-23*. Each forward  
752 reading frame is labelled; F1, F2 or F3. Each ORF is shown to scale as a box, numbered with the  
753 gene number. Each STOP codon is represented as a green vertical line. The positions of the  $\Phi$ M1  
754 escape phage mutations are shown by red vertical lines, labelled with the parent phage. The scale  
755 is in base pairs.

756

757 FIG 2 ToxI<sub>Pa</sub> levels are affected during phage infection. (A) S1-nuclease assay targeting the full  
758 5.5 repeat ToxI<sub>Pa</sub> sequence was used to monitor ToxI<sub>Pa</sub> levels during  $\Phi$ M1 infection. Assays  
759 were performed on 10  $\mu$ g total RNA prepared from Pba ToxIN<sub>Pa</sub> (pMJ4) at different times  
760 following  $\Phi$ M1 infection. Numbers indicate the time (min) after infection with phage (+  $\Phi$ M1)  
761 and the negative control without phage (-  $\Phi$ M1). Hybridization to total RNA from Pba  
762 expressing ToxIN<sub>Pa</sub> (pTA46) and DH5 $\alpha$  served as positive and negative controls, respectively.  
763 The expression of ToxN<sub>Pa</sub> at the respective time points of infection is shown in the lower panel  
764 using Western Blot; C indicates the 11 kDa SdhE-FLAG protein used as a loading and size

765 control (41). (B) S1-nuclease assay targeting  $ToxI_{Pa}$  for the infection with the escape phage  
766  $\Phi M1-O$ . The assay was done as in (A).

767

768 FIG 3 Toxicity of the  $\Phi M1$  escape locus products. (A) The escape locus of  $\Phi M1$  as per Fig. 1B.  
769 The positions of the  $\Phi M1$  escape phage mutations are shown by red vertical lines, labelled with  
770 the parent phage. The scale is in base pairs. (B) Specific regions of the phage genomes,  
771 designated by the length of the line that corresponds to the genomic locus shown in (A), were  
772 cloned into pBAD30 to make nine different constructs. Blue dotted lines in (A) reflect the  
773 construct boundaries in (B). The figure is drawn to scale. (C) Expression of  $\Phi M1$  wt and  $\Phi M1-B$   
774 escape loci in *Pba*. Strains of *Pba* containing either a  $ToxIN_{Pa}$  or  $ToxIN_{Pa}$ -FS plasmid (pTRB125  
775 or pTRB126), together with a phage construct (or pBAD30 vector control) were tested for  
776 toxicity. (D) A range of construct 7 plasmids was tested for toxicity in *Pba*. The escape phage  
777 constructs were all reduced for toxicity. Error bars show the standard deviation in triplicate data.

778

779 FIG 4 Co-immunoprecipitation of M1-23, M1-O-23 and UvrA. (A), and (B) show co-  
780 immunoprecipitation experiments with wild type M1-23 and UvrA. In (A) M1-23-6His was used  
781 as the bait and attached to a  $Ni^{+}$  column with UvrA-FLAG passed through. In (B) the reciprocal  
782 experiment was performed with UvrA-6His used as the bait and M1-23-FLAG was passed  
783 through. (C), and (D) show the same co-immunoprecipitation experiments using M1-O-23  
784 instead of M1-23. In (C) M1-O-23 was used as the bait and in (D) UvrA-6His was used as bait.

785

786 **Tables**

TABLE 1 Bacterial strains and bacteriophages used in this study

Bacteria	Genotype/ Characteristics	Source
<i>E. coli</i> $\beta$ 2163	F <sup>-</sup> RP4-2-Tc::Mu <i>dapA</i> ::( <i>erm-pir</i> ), Km <sup>R</sup>	(57)
<i>E. coli</i> DH5 $\alpha$	F <sup>-</sup> <i>endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20 <math>\phi</math>80d lacZ<math>\Delta</math>M15 <math>\Delta</math>(lacZYA-argF)U169, hsdR17(<i>r<sub>K</sub><sup>-</sup>m<sub>K</sub><sup>+</sup></i>), <math>\lambda</math><sup>-</sup></i>	Gibco/BRL
<i>E. coli</i> ER2566	F <sup>-</sup> $\lambda$ - <i>thuA2 [lon] ompT lacZ::T7 gene 1 gal sulA11 <math>\Delta</math>(mcrC-mrr)114::IS10 R(mcr-73::miniTn 10-TetS)2 R(zgb-210::Tn10)(TetS) endA1 [dcm]</i>	NEB
<i>E. coli</i> W3100	F <sup>-</sup> $\lambda$ - <i>rph-1 INV(rrhD, rrhE)</i>	(58)
<i>Pectobacterium atrosepticum</i> SCRI1043	Wild type strain	(31)
Phages	Characteristics	Source
$\Phi$ M1	Podoviridae, propagated on wt SCRI1043	(30)
$\Phi$ M1-A	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	(29)
$\Phi$ M1-B	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	(29)
$\Phi$ M1-C	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	(29)
$\Phi$ M1-D	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	(29)
$\Phi$ M1-O	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-V	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-W	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-X	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-Y	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-Z	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-Q	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-E1 to E49	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1	This study
$\Phi$ M1-U1	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U2	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U4	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U5	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U6	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U7	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U8	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U9	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-U10	ToxIN <sub>P<sub>a</sub></sub> -escape mutant of $\Phi$ M1 on UvrA mutant	This study
$\Phi$ M1-PL2	TenpIN <sub>P<sub>I</sub></sub> -escape mutant of $\Phi$ M1	This study

787

TABLE 2 Primers used in this study

Primer	Sequence (5'-3')	Description	Restriction site
KDOI	TTTTGGATCCGTTTTATCGACATTGTGAACC	<i>toxIN</i> locus	<i>Bam</i> HI
PF147	GTATCTAGAGTAGTCGCCTCTTTACTTTATTA C	<i>toxI</i>	<i>Xba</i> I
PF217	TTGTATACTTAAGTTATTGACTCTATAGCTCAG	ToxI amplification for S1-nuclease protection assay	<i>Hind</i> III
PF218	TTGACTATGTAGTCGCCTCTTTACTTTATTTTC GAACCTCGGACCTGCG	ToxI amplification for S1-nuclease protection assay	<i>Drd</i> I
TRB37	CCGGCATATGAAATTCTACACTATATCAAGC	Used for ToxIN CBD	<i>Nde</i> I
TRB38	GTGGTTGCTCTTCCGCACTCGCCTTCTCCGTAT	Used for ToxIN CBD	<i>Sap</i> I
TRB107	TTGAATTCTGCGCAAGCAACTGGTGACCC	ΦM1 sequencing primer	<i>Eco</i> RI
TRB108	TTAAGCTTCTTGAATCTGACTCACCG	ΦM1 sequencing primer	<i>Hind</i> III
TRB111	TTGAATTCCTGTAGGAGCGTGAATGC	ΦM1 escape locus	<i>Eco</i> RI
TRB115	TTGAATCCAGGGGTGTACCTACTCC	ΦM1 sequencing primer	<i>Eco</i> RI
TRB116	TTAAGCTTGTAAGTGTGACGTGATACC	ΦM1 sequencing primer	<i>Hind</i> III
TRB117	TTGAATCCCTACAATGCCCCAGATGC	ΦM1 escape locus	<i>Eco</i> RI
TRB118	TTAAGCTTACGGTCGTAAGTGGCTTCG	ΦM1 escape locus	<i>Hind</i> III
TRB125	TTAAGCTTCTAATCCTACGCCTTGTGC	ΦM1 escape locus	<i>Hind</i> III
TRB126	TTGAATTCAGGTGGATGCAACTCGGG	ΦM1 escape locus	<i>Eco</i> RI
TRB127	TTAAGCTTCTCTACATCATCCAACATC	ΦM1 escape locus	<i>Hind</i> III
TRB128	TTGAATTCGAGCTGCGTGATGAGTTCC	ΦM1 escape locus	<i>Eco</i> RI
TRB129	TTGAATTCGCTTACCCGATTATATCC	ΦM1 escape locus	<i>Eco</i> RI
TRB130	TTGAATCCCAATTTAAAATTAATGA	ΦM1 escape locus	<i>Eco</i> RI
TRB134	TTAAGCTTATTACTTGTGCATCGTCGTCCTTGT GTCTCCTAGGTACCCCATCTGG	ΦM1 construct 7/ORF23 FLAG	<i>Hind</i> III
TRB135	TTAAGCTTAGTGATGGTGATGGTGATGCCTCC TAGGTACCCCATCTGG	ΦM1 construct 7/ORF23-6His	<i>Hind</i> III
TRB332	TTAAGCTTATTACTTGTGCATCGTCGTCCTTGT GTCTCCAGCATCGGCTTAAGGAAGCG	<i>uvrA</i> -FLAG	<i>Hind</i> III
TRB337	ATTAGGATCCGATAAGATCGAAGTTTCG	<i>uvrA</i> primer	<i>Bam</i> HI
TRB338	ATTAAGCTTTTACAGCATCGGCTTAAG	<i>uvrA</i> primer	<i>Hind</i> III
UvrA dnF	TTTATTCCGGGAAGTGTGTGAATTTAAATTAG CGAGAGGCCAAATCATG	Fwd, 500bp downstream of <i>uvrA</i>	<i>Swa</i> I
UvrA dnR	TTATCAGAATTCCTGCCGTGCAGGCAGTTCAG	Rev, 500bp downstream of <i>uvrA</i>	<i>Eco</i> RI
UvrA upF	TTATCATCTAGATTGCAGTGCCTTCGATG	Fwd, 500bp upstream of <i>uvrA</i>	<i>Xba</i> I
UvrA upR	CATGATTTGGCCTCTCGCTAATTTAAATTCACA CACTTCCCGGAATAAA	Rev, 500bp upstream of <i>uvrA</i>	<i>Swa</i> I

788

TABLE 3 Plasmids used in this study

Name	Description	Construction	Template	Resistance
pACYC184	Cloning vector	(59)	-	Cm
pBR322	<i>E. coli</i> cloning vector	NEB	-	Ap, Tc
pFR2	<i>Photothabdus luminescens</i> TT01 full TenpIN <sub>Pi</sub> locus	(23)	pBR322	Ap
pKNG-uvrA	UvrA marker exchange construct	UvrA upF, UvrA upR, UvrA dnF, UvrA dnR	pKNG101	Tc, Kan
pKNG101-Tc <sup>R</sup>	Marker exchange suicide vector	(60)	-	Tc
pMAT7	SdhE-FLAG expression vector	(41)	pBAD30	Ap
pMJ4	toxI <sub>Pa</sub> , ToxN <sub>Pa</sub> -FLAG with native promoter in pBR322	(29)	pBR322	Ap
pQE80L	Protein expression vector	Qiagen	-	Ap
pRW50	Promoterless LacZ	(49)	-	Tc
pTA46	ToxIN <sub>Pa</sub> with native promoter	(29)	pBR322	Ap
pTA104	ToxIN <sub>Pa</sub> promoter	(22)	pRW50	Tc
pTA110	In vitro transcription vector for antisense ToxI <sub>Pa</sub> RNA	PF217, PF218	pBSII SK <sup>-</sup>	Ap
pTRB18-KP14	ToxI <sub>Pa</sub> containing	KDO1, PF147	pACYC184	Cm, Tt
pTRB14	ToxN <sub>Pa</sub> CBD	TRB37, TRB38	pTA46	Ap
pTRB113	ΦM1 wt construct 3	TRB126+TRB118	pBAD30	Ap, glu
pTRB114	ΦM1 wt construct 4	TRB117, TRB127	pBAD30	Ap, glu
pTRB115	ΦM1 wt construct 5	TRB126, TRB125	pBAD30	Ap, glu
pTRB116	ΦM1 wt construct 6	TRB128, TRB118	pBAD30	Ap, glu
pTRB121	ΦM1-B construct 2	TRB117, TRB125	pBAD30	Ap, glu
pTRB123	ΦM1-B construct 4	TRB117, TRB127	pBAD30	Ap, glu
pTRB124	ΦM1-B construct 5	TRB126, TRB125	pBAD30	Ap, glu
pTRB133	ΦM1 wt construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB134	ΦM1 wt construct 8	TRB129, TRB125	pBAD30	Ap, glu
pTRB135	ΦM1 wt construct 9	TRB130, TRB125	pBAD30	Ap, glu
pTRB136	ΦM1-A construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB139	ΦM1-B construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB140	ΦM1-B construct 8	TRB129, TRB125	pBAD30	Ap, glu
pTRB141	ΦM1-B construct 9	TRB130, TRB125	pBAD30	Ap, glu
pTRB148	ΦM1 wt construct 7-FLAG	TRB111, TRB134	pBAD30	Ap, glu
pTRB151	ΦM1-O construct 7-FLAG	TRB111, TRB134	pBAD30	Ap, glu
pTRB153	ΦM1-W construct 7-FLAG	TRB111, TRB134	pBAD30	Ap, glu
pTRB154	ΦM1-Y construct 7-FLAG	TRB111, TRB134	pBAD30	Ap, glu
pTRB155	ΦM1-D construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB156	ΦM1-O construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB157	ΦM1-V construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB158	ΦM1-W construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB159	ΦM1-Y construct 7	TRB111, TRB125	pBAD30	Ap, glu
pTRB160	ΦM1 wt LacZ fusion construct	TRB117, TRB127	pRW50	Tc
pTRB161	ΦM1 wt LacZ fusion construct	TRB111, TRB127	pRW50	Tc
pTRB162	ΦM1 wt LacZ fusion construct	TRB126, TRB127	pRW50	Tc
pTRB163	ΦM1-O LacZ fusion construct	TRB117, TRB125	pRW50	Tc
pTRB164	ΦM1 wt LacZ fusion construct	TRB117, TRB125	pRW50	Tc
pTRB189	ΦM1-23-6His	TRB111, TRB135	pQE-80L	Ap
pTRB190	ΦM1-O-23-6His	TRB111, TRB135	pQE-80L	Ap
pTRB300	UvrA-FLAG	TRB330, TRB332	pBAD33	Cm, glu
pTRB301	UvrA-6His	TRB337, TRB338	pQE-80L	Ap

789



TABLE 4 Summary of  $\Phi$ M1 escape mutations and effects on reading frames

Phage	Date of isolation	Mutation relative to $\Phi$ M1 wt	Effect on forward reading frames <sup>a</sup>		
			F1	F2	F3
$\Phi$ M1-A	Mar 2007	15416 A to C	Y to S	T to P	No change
$\Phi$ M1-B	Mar 2007	15292 C to T	R to STOP	No change	P to L
$\Phi$ M1-C	Mar 2007	15170 T to C	M to T	STOP to S	No change
$\Phi$ M1-D	Mar 2007	15410 T to C	M to T	W to R	No change
$\Phi$ M1-O	Jun 2009	15407 A to C	Q to P	No change	No change
$\Phi$ M1-V	May 2009	15415 T to G	Y to D	No change	V to G
$\Phi$ M1-W	May 2009	15398 A to T	D to V	M to L	STOP to C
$\Phi$ M1-X	May 2009	15288 AA to A	FS to STOP after 9 aa (wild type F1 continues <i>phiM1-23</i> )	FS causing Q to H and STOP after 3 aa (wild type F2 stops after 9 aa)	FS causing N to T and shift of ORF1 into ORF2 (wild type F3 stops after 3 aa)
$\Phi$ M1-Y	May 2009	15397 G to A	D to N	No change	No change
$\Phi$ M1-Z	May 2009	15416 A to G (cf M1-A)	Y to C	T to A	No change

<sup>a</sup> 'FS', frameshift; 'aa', amino acid

790

TABLE 5 EOPs against ToxIN<sub>Pa</sub> and TenpIN<sub>Pi</sub> Type III TA systems

Phage	EOP vs ToxIN <sub>Pa</sub>	EOP vs TenpIN <sub>Pi</sub>	Escape selected on
ΦM1 wt	$1.3 \times 10^{-5}$	$1.1 \times 10^{-2}$	-
ΦS61	$<3.2 \times 10^{-9}$	0.9	-
ΦTE	$1.0 \times 10^{-8}$	0.7	-
ΦM1-O	1.0	1.0	ToxIN <sub>Pa</sub>
ΦM1-PL2	0.9	0.9	TenpIN <sub>Pi</sub>

791




FIG 1 Genomic map of  $\Phi$ M1 wild type and its escape locus.




FIG 2 ToxI<sub>pa</sub> levels are affected during phage infection.




FIG 3 Toxicity of the  $\Phi$ M1 escape locus products.




FIG 4 Co-immunoprecipitation of M1-23, M1-O-23 and UvrA.